Innogenetics extends collaboration with IDM Pharma for the development of its next generation therapeutic vaccines
Innogenetics announced that it has extended its collaboration with IDM Pharma Inc., formerly Epimmune Inc., by a further six months to March 2006 to generate polyepitope-based therapeutic vaccine candidates for use in the treatment of chronic human papillomavirus and hepatitis C infections.
In March 2004, Innogenetics announced that it had acquired the therapeutic vaccine programs of U.S.-based Genencor International, Inc. (now part of Danisco A/S) by which it gained access to a broad technology platform, intellectual property rights, and licenses with respect to vaccine applications for hepatitis B virus (HBV), human papillomavirus (HPV), and hepatitis C virus (HCV). As part of this deal, Innogenetics also acquired exclusive access to a broad portfolio of immunotherapeutic tools that were developed by Genencor's partner Epimmune (now IDM Pharma) to be further optimized together with Innogenetics.
This collaboration with IDM Pharma will now be extended for a further 6 months until end-March 2006 in order to enable Innogenetics to complete its development efforts to generate polyepitope-based therapeutic vaccine candidates.
Other news from the department business & finance
